RGT-61159

Phase 1Small molecule

RRgenta Therapeutics Inc

RGT-61159 is one of 37 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adenoid Cystic CarcinomaActive, not recruiting

Adenoid Cystic CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Adenoid Cystic Carcinoma

#DrugCompanyPhaseTrials

Afinitor

Adriamycin

Lenvima

4 4

Keytruda

Merck & Co.

Phase 2

2 5

TKI258

Novartis

Phase 2

2 6

Padcev

Pfizer

Phase 2

1 7

Sutent

Pfizer

Phase 2

1 8

Ellence

Pfizer

Phase 2

1 9

Gleevec

Novartis

Phase 2

1 10

Rybrevant

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Adenoid Cystic Carcinoma

NCT06462183

Clinical

Trials by Indication[1]

Adenoid Cystic Carcinoma1 trial

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Recruiting·RRgenta Therapeutics Inc·Phase 1·NCT06462183·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RGT-61159. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RGT-61159 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RGT-61159. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rgenta Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRgenta Therapeutics Inc

RGT-61159

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Adenoid Cystic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News